



April 17, 2018

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

The National Stock Exchange of India Limited

Exchange Plaza, Bandra Kurla Complex,
Bandra (E),
Mumbai - 400 051

Scrip code: 512529

Scrip code: SEQUENT

Dear Sir/ Madam,

**Sub: Press Release - SeQuent Scientific announces acquisition of Bremer Pharma
in Germany**

We are pleased to enclose hereby a press release of the Company titled "**SeQuent Scientific
announces acquisition of Bremer Pharma in Germany**"

Kindly take the same on record.

Thanking you,

Yours faithfully,
For Sequent Scientific Limited

Krupesh Mehta
Company Secretary

Encl: A/a

SeQuent Scientific Limited

Registered Office: 301/A, 'Dosti Pinnacle', Plot No. E7, Road No. 22, Wagle Industrial Area, Thane (W), Mumbai - 400604, India
Tel.: +91-22-41114777 | **Fax:** +91-22-41114754 | **CIN:** L99999MH1985PLC036685
<http://www.sequent.in>

SeQuent Scientific announces acquisition of Bremer Pharma in Germany

Mumbai, April 17, 2018

SeQuent Scientific Limited (SeQuent), today announced that its wholly owned subsidiary Alivira Animal Health Limited (“Alivira”) through Alivira Ireland, has today signed an agreement with simultaneous closing to acquire 100% of Bremer Pharma, Zydus Cadila’s Animal Health Business in Germany.

Bremer Pharma, founded in 1982 is a niche veterinary health company in Germany with focus on cattle and swine segments. Bremer has a portfolio of over 400+ registered products across Europe, Far East, MENA, Russia & Africa operating in vitamins, antibiotics and hormones. Bremer registered sales of €6.7Mn (\$8.3Mn) in year ending March 31, 2018 with marginal losses. Bremer comes with a EUGMP compliant injectable manufacturing facility with approval from German Competent Authority LANUV. The site was recently re-inspected and obtained a renewed GMP certificate on 12th March 2018.

This acquisition provides Alivira’s with a beta-lactam & non-beta lactam injectables facility for EU markets, which compliments its Orals & Powders beta-lactam and non-beta lactam facility based at Barcelona in Spain. EU is Alivira’s largest market accounting to 60% of revenues.

With this acquisition, Alivira is a ~\$150 Mn business on annualized basis with presence in 95+ countries. Alivira has strong presence in the formulations business in key veterinary markets of Europe, LATAM, India, Turkey, Africa and South East Asian countries. Over 80% of the revenues of Alivira are generated outside India, with manufacturing operations in Spain, Germany, Brazil, India and Turkey and R&D development in India, Turkey and Spain.

In last 36 months Alivira has successfully acquired and integrated over 8 businesses globally. These successful integrations, coupled with commercialization of API’s in US and aggressive new product development program will create sustainable value and speed up the revenue and margin growths in the coming years.

*Commenting on the acquisition, **Manish Gupta, Managing Director** said ‘**We are excited with the addition of Bremer Pharma to the Alivira fold as it consolidates our position as a leading Animal Health Company in the European market.** This also provides comprehensive manufacturing footprint in EU across Injectables, Orals, Solids, and Powder range and front-end presence in Top 6 of 10 EU markets. The scale up and growth momentum will further drive the next phase of value creation through accelerated revenues and margin expansion in the business.’*

About SeQuent Scientific Limited

SeQuent Scientific Limited (BSE-512529, NSE-SEQUENT) headquartered in Mumbai, India with a global footprint, operates in the domains of Animal Health (Alivira) and Analytical Services. SeQuent has seven manufacturing facilities based in India, Spain, Germany, Brazil and Turkey with approvals from global regulatory bodies including USFDA, EUGMP, WHO, TGA among others. Its API facility at Vizag is India's first and only USFDA approved facility for veterinary APIs.

The human API business of Sequent was recently demerged into Solara Active Pharma Sciences Ltd. (SAPS), with an appointed date of 1st October 2017.

For details, feel free to contact:

Tushar Mistry

Chief Financial Officer

Tel: +91 22 41114717

tushar.m@sequent.in

Shivangi Bubna

Christensen Investor Relations

Tel : +91 22 4215 0210

sbubna@christensenir.com

Registered Office

301/A, 'Dosti Pinnacle', Plot No. E7, Road No. 22,
Wagle Industrial Area, Thane (W), Maharashtra,
India

CIN: L99999MH1985PLC036685

BSE Code:512529 | NSE: SEQUENT

ISIN: INE807F01027 | REUTERS: EQU.BO

Website: www.sequent.in

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. SeQuent Scientific Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.